Select language:

Clinical trials of nasal vaccine started in Moscow

 / Главная / Russkiy Mir Foundation / News / Clinical trials of nasal vaccine started in Moscow

Clinical trials of nasal vaccine started in Moscow


27.01.2022

Photo by M. Mishin. Press Service of the Mayor and Government of Moscow / mos.ru (CC BY 4.0)

Clinical trials of a COVID-19 nasal vaccine developed by the Gamaleya National Research Center for Epidemiology and Microbiology have started in Moscow. About 400 people are taking part in it the tests. The trials are conducted at Sechenov University, the active phase of the study will take place within 180 days, TASS reports.

According to Moscow's authorities, a nasal vaccine does not differ from other COVID-19 drugs. According to preclinical data, the spray vaccine has fewer adverse reactions than previous formulas.

One of the advantages of the nasal vaccine administration is that it does not require special equipment and sterility.

Russkiy Mir

News by subject

Publications

Marco Maggi: ”Russian to the Bone" 20.01.2024
Italian entrepreneur Marco Maggi's book, "Russian to the Bone," is now accessible for purchase in Italy and is scheduled for release in Russia in the upcoming months. In the book, Marco recounts his personal odyssey, narrating each stage of his life as a foreigner in Russia—starting from the initial fascination to the process of cultural assimilation, venturing into business, fostering authentic friendships, and ultimately, reaching a deep sense of identifying as a Russian at his very core.